Literature DB >> 8617299

CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition.

M Chilosi1, F Facchetti, L D Notarangelo, S Romagnani, G Del Prete, F Almerigogna, M De Carli, G Pizzolo.   

Abstract

Omenn's syndrome (OS) is a severe immunodeficiency, characterized by clinical and laboratory features reminiscent of a T helper type-2 (Th2) response. CD30, a member of the tumor necrosis factor receptor superfamily, has been found to be preferentially expressed by human T cell clones exhibiting a Th2-line profile and function. We investigated whether there are derangement in CD30 expression in tissues, and/or abnormalities in soluble CD30 (sCD30) levels in the serum, or both, of three children with OS and one child with maternal engraftment and Omenn's-like syndrome (OLS). Large proportions of tissue-infiltrating T lymphocytes from all four patients expressed CD30, whereas in control tissues, including peripheral blood, CD30+ T lymphocytes were extremely few or absent. In addition, levels of sCD30 were abnormally increased in all patients' sera. T cell clones were generated from sorted CD30+ and CD30-peripheral blood T cells of the patient with OLS who showed unusually high numbers of circulating CD30+ T lymphocytes. Most CD4+ T cell clones derived from CD30+ cells showed a Th2-like cytokine profile, whereas the majority of clones generated from CD30-T cells were Th1. These findings support the hypothesis that Th2 cells are involved in the pathogenesis of OS. Moreover, they provide evidence that detection of CD30+ T cells in tissues, increased levels of sCD30 in biological fluids, or both, reflect the presence of immune responses characterized by prevalent activation of T cells producing Th2 cytokines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617299     DOI: 10.1002/eji.1830260209

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  35 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.

Authors:  E J Croager; A M Gout; L J Abraham
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

3.  The effect of IL-18 on IL-12-induced CD30 expression and IL-4 and IFN-gamma production by allergen and PPD specific T cells.

Authors:  M Tarkowski; S Chrul; J Bodalski
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

4.  Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  R Zemble; E Luning Prak; K McDonald; D McDonald-McGinn; E Zackai; K Sullivan
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

5.  Expression of CD30 mRNA, CD30L mRNA and a variant form of CD30 mRNA in restimulated peripheral blood mononuclear cells (PBMC) of patients with helminthic infections resembling a Th2 disease.

Authors:  J Kilwinski; T Berger; J Mpalaskas; S Reuter; W Flick; P Kern
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 6.  RAG gene defects at the verge of immunodeficiency and immune dysregulation.

Authors:  Anna Villa; Luigi D Notarangelo
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

7.  A variant of SCID with specific immune responses and predominance of gamma delta T cells.

Authors:  Stephan Ehl; Klaus Schwarz; Anselm Enders; Ulrich Duffner; Ulrich Pannicke; Joachim Kühr; Françoise Mascart; Annette Schmitt-Graeff; Charlotte Niemeyer; Paul Fisch
Journal:  J Clin Invest       Date:  2005-10-06       Impact factor: 14.808

8.  Matched unrelated bone marrow transplant for Omenn syndrome.

Authors:  Amit Nahum; Brenda Reid; Eyal Grunebaum; Chaim M Roifman
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

9.  Lack of iNKT cells in patients with combined immune deficiency due to hypomorphic RAG mutations.

Authors:  Ponpan Matangkasombut; Muriel Pichavant; Doris E Saez; Silvia Giliani; Evelina Mazzolari; Andrea Finocchi; Anna Villa; Cristina Sobacchi; Patricia Cortes; Dale T Umetsu; Luigi D Notarangelo
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

Review 10.  Human RAG mutations: biochemistry and clinical implications.

Authors:  Luigi D Notarangelo; Min-Sung Kim; Jolan E Walter; Yu Nee Lee
Journal:  Nat Rev Immunol       Date:  2016-03-21       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.